Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Lexicon (LXRX) discussed its Q2 2026 earnings call, focusing on sotagliflozin. The company said SONATA-HCM enrollment is complete and the trial was overenrolled, with top-line results expected in Q1 2027. For Zynquista, Lexicon said FDA resubmission criteria may be met after STENO1 reaches exposure targets by end of August, targeting an NDA resubmission in Q4 2026. It also noted Viatris regulatory progress for sotagliflozin and Novo Nordisk’s Phase I for 9851.

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pressreleaseearningsq208-0.htm EX-99.1 Document Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities f

Lexicon (LXRX) reported Q1 2026 revenue of $21.1M, up from $1.3M, driven by two $10M Novo Nordisk milestone payments and $1.1M INPEFA sales. R&D fell to $12.8M and SG&A to $9.2M. Net loss narrowed to $1.0M. Cash rose to $199.7M after a capital raise and $100M Hercules Capital refinancing; total debt fell to $49.7M. SONATA Phase III enrollment targets 500 patients by midyear; Zynquista NDA resubmission is on track for midyear.

Foreign banks are seeking larger roles in Vietnam by extending hard-currency loans to local lenders facing higher domestic funding costs and credit-expansion pressure. Fitch’s Willie Tanoto cited syndicated deals of several hundred million dollars. Examples include HDBank’s $721 million loan and VPBank’s $1.44 billion loan, with Techcombank seeking $1 billion pending approval.

Medicus Pharma (NASDAQ:MDCX) reported Q2 2026 progress in its SkinJect and Teverelix programs, including FDA “Study May Proceed” for a registrational SkinJect study in Gorlin Syndrome and UAE/IRB approvals for Teverelix Phase 2 work. Cash was $25.2M at June 30. Net loss was $11.7M ($0.21/share). The company raised about $40M in H1 2026 and warned of going-concern risk.

Phillips 66 and Kinder Morgan reached a final investment decision for the $5 billion Western Gateway Pipeline to ship gasoline and other refined products from Texas to Arizona and California. Phillips 66 will own 49.9%, Kinder Morgan 35.1%, and HF Sinclair 15% via the JV. The project links multiple refineries to terminals in El Paso, Tucson/Phoenix, Colton and Las Vegas.